NCT06483906View on ClinicalTrials.gov

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax, Azacitidine and Homoharringtonine

Patients will receive the VAH regimen for the treatment of AML

Trial Locations (1)

Unknown

RECRUITING

Shanghai General hospital,Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER